<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606928</url>
  </required_header>
  <id_info>
    <org_study_id>mFLOT-GC</org_study_id>
    <nct_id>NCT03606928</nct_id>
  </id_info>
  <brief_title>mFLOT Chemotherapy as First-line Treatment in GC</brief_title>
  <official_title>Modified FLOT Chemotherapy as First-line Treatment in Advanced or Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center phase 1b/2 trail to identified suitable dosage and its efficacy of modified
      FLOT regime in Chinese gastric cancer patients. This trial is designed to identified
      recommended phase II dose (RP2D) of modified FLOT in Chinese patients, and to evaluate the
      efficacy of modified FLOT regime as first-line for advanced or metastatic gastric cancer.

      This trial is in 2 stages: the first stage will establish the maximum tolerated dose (MTD)
      and RP2D of docetaxel and oxaliplatin in FLOT regime. In the second stage, the efficacy of
      modified FLOT will be assessed by response rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RP2D of FLOT regime will be established with a standard 3+3 design, starting with the
      dose of 40mg/m2 docetaxel (dose level 1) and 65mg/m2 oxaliplatin (dose level 1). The plan of
      dose escalation will be found in following table. Chemotherapy will be administered
      two-weekly (maximum 12 cycles) until progression of disease, intolerable toxicity or withdraw
      of patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">November 9, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose and recommended phase II dose of modified FLOT regime</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>modified FLOT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modified FLOT Docetaxel 40mg/m2 ivgtt day 1 over 1 hour Oxaliplatin 65mg/m2 ivgtt day 1 over 2hours Dose escalation will be performed. Leucovorin 200mg/m2 ivgtt day 1 over 2 hours 5-FU 2200mg/m2 civ over 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, oxaliplatin, 5-FU, leucovorin</intervention_name>
    <description>This is a single-arm study with all patients receiving mFLOT chemotherapy.</description>
    <arm_group_label>modified FLOT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male/female patients aged from 18 to 75 years.

          2. Histologically confirmed gastric adenocarcinoma.

          3. Gastric tumors should be treatment naïve unresectable or metastatic disease, or
             recurrence over 6 months after finish of adjuvant chemotherapy.

          4. At least one measurable lesion should be confirmed by imaging examination.

          5. ECOG performance status 0 or 1

          6. Adequate bone marrow function:

             Absolute neutrophil count (ANC) ≥1.5x109/L White blood count ≥3.5x109/L Platelets
             ≥80x109/L Hemoglobin (Hb) ≥90g/L (can be post-transfusion)

          7. Adequate renal function: Creatinine Clearance of &gt;50ml/min

          8. Adequate liver function:

        Serum bilirubin &lt;22 umol/L ALT/AST ≤2.5x ULN, for patient with liver metastasis ALT/AST ≤5x
        ULN 10. Adequate coagulation profile International Normalised Ratio (INR) &lt; 1.5 Activated
        Prothrombin Time (APTT) &lt; 1.5xULN 11. Without brain metastasis and peripheral nerve
        diseases 12. Willingness and ability to comply with the protocol for the duration of the
        study including scheduled visits, examinations, investigations and treatment plans with
        informed consent form.

        Exclusion Criteria:

          1. With second primary malignant diseases

          2. Any contraindication or known hypersensitivity reaction to any of the study drugs, or
             components of leucovorin, oxaliplatin, 5-FU or docetaxel

          3. With uncontrollable complications

          4. Inadequate organ function

          5. Pregnancy or of child bearing potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhang, MD &amp; Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Jun Zhang</investigator_full_name>
    <investigator_title>Chief, Department of Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We have no plan to make individual participant data (IPD) available to other researchers.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03606928/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03606928/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

